Literature DB >> 20085388

Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit.

Devidas Menon1, Christopher J McCabe, Tania Stafinski, Richard Edlin.   

Abstract

Mesh：

Year:  2010        PMID： 20085388     DOI： 10.2165/11530860-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

1.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.

Authors:  Cathie L M Sudlow; Carl E Counsell
Journal:  BMJ       Date:  2003-02-15

2.  Access with evidence development: the US experience.

Authors:  Penny E Mohr; Sean R Tunis
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Access with evidence development in the UK: past experience, current initiatives and future potential.

Authors:  Andrew Briggs; Karen Ritchie; Elisabeth Fenwick; Kalipso Chalkidou; Peter Littlejohns
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Access with evidence development schemes: a framework for description and evaluation.

Authors:  Christopher J McCabe; Tania Stafinski; Richard Edlin; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 5.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981
  5 in total
  8 in total

1.  Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.

Authors:  Tania Stafinski; Devidas Menon; Caroline Davis; Christopher McCabe
Journal:  Clinicoecon Outcomes Res       Date:  2011-08-30

2.  Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.

Authors:  Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Access with evidence development: the US experience.

Authors:  Penny E Mohr; Sean R Tunis
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  We know accurately only when we know little.

Authors:  Stuart MacLeod; Craig Mitton
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013.

Authors:  Urs Brügger; Bruno Horisberger; Alexander Ruckstuhl; Rafael Plessow; Klaus Eichler; Alois Gratwohl
Journal:  BMJ Open       Date:  2015-03-27       Impact factor: 2.692

6.  Access to new cancer medicines in Australia: dispelling the myths and informing a public debate.

Authors:  Agnes Vitry; Barbara Mintzes; Wendy Lipworth
Journal:  J Pharm Policy Pract       Date:  2016-04-07

7.  Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews.

Authors:  Danielle Bishop; Joel Lexchin
Journal:  BMC Health Serv Res       Date:  2013-03-09       Impact factor: 2.655

Review 8.  When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.

Authors:  Louise Longworth; Jihee Youn; Laura Bojke; Stephen Palmer; Susan Griffin; Eldon Spackman; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.